September 1, 2021
Natick biotech co. closes $53M in financing for stem cell product
Photo | Google Maps
HebeCell Corp.'s headquarters in Natick
By Katherine Hamilton
HebeCell Corp., a Natick research company focused on therapies for cancer and autoimmune disease, announced on Tuesday it has closed a $53-million Series A financing for an off-the-shelf stem cell product.
The investment was led by Jacobio Pharmaceuticals, headquartered in China, who will collaborate with HebeCell to develop the (PSC)-CAR-NK therapy, according to the press release.
The treatment is a form of natural killer cell, which helps activate the immune system against abnormal cells. NK cells are used to treat cancer, viral infection, and autoimmune diseases.
HebeCell was founded in 2016 and is focused on making NK cell therapeutics affordable and available to clinics worldwide.
WBJ Web Partners
Most Recent
Most Recent
0 Comments